Outcomes After Aspirin Discontinuation Among Baseline Users in Contemporary Primary Prevention Aspirin Trials: A Meta-Analysis

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2024 Feb 26

PMID 38408145

Authors

Ruth Campbell

Mark R Nelson

John J McNeill

John W McEvoy

Affiliations

Soon will be listed here.

Citing Articles

Deprescribing Cardiovascular Medications in Older Adults Living with Frailty.

Ho K, Mallery L, Trenaman S, Searle S, Bata I CJC Open. 2024; 6(12):1503-1512.

PMID: 39735941 PMC: 11681363. DOI: 10.1016/j.cjco.2024.09.008.

Guideline concordance of aspirin use for primary prevention in adult outpatients.

Chipalkatti N, Barnes G, Bashaw L, Davie A, Griggs J, Harrod M Blood Adv. 2024; 8(24):6207-6214.

PMID: 39374577 PMC: 11697097. DOI: 10.1182/bloodadvances.2024014220.

Short- and long-term impact of aspirin cessation in older adults: a target trial emulation.

Zhou Z, Webb K, Nelson M, Woods R, Ernst M, Murray A BMC Med. 2024; 22(1):306.

PMID: 39075484 PMC: 11287830. DOI: 10.1186/s12916-024-03507-8.

References

McNeil J, Wolfe R, Woods R, Tonkin A, Donnan G, Nelson M . Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018; 379(16):1509-1518. PMC: 6289056. DOI: 10.1056/NEJMoa1805819. View

Nelson M, Polekhina G, Woods R, Reid C, Tonkin A, Wolfe R . Safety of Ceasing Aspirin Used Without a Clinical Indication After Age 70 Years: A Subgroup Analysis of the ASPREE Randomized Trial. Ann Intern Med. 2022; 175(5):761-764. PMC: 9434500. DOI: 10.7326/M21-3823. View

Sundstrom J, Hedberg J, Thuresson M, Aarskog P, Johannesen K, Oldgren J . Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study. Circulation. 2017; 136(13):1183-1192. DOI: 10.1161/CIRCULATIONAHA.117.028321. View

Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J . Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018; 379(16):1529-1539. DOI: 10.1056/NEJMoa1804988. View

Gaziano J, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick P . Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018; 392(10152):1036-1046. PMC: 7255888. DOI: 10.1016/S0140-6736(18)31924-X. View